Drug Profile
Research programme: oral therapeutics - Bionex Pharmaceuticals
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Bionex Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mycoses; Pain
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Mycoses in USA (PO, Lozenge)
- 28 Dec 2020 No recent reports of development identified for research development in Pain in USA (PO, Lozenge)
- 15 Nov 2016 Early research in Mycoses in USA (PO) before November 2016